Insider · CIK 0001667937
Faraz Ali
Files at TNYA (Tenaya Therapeutics, Inc.). First filing Feb 16, 2024, latest Aug 17, 2026.
In brief
Faraz Ali files SEC Form 4 as CEO and director at TNYA (Tenaya Therapeutics, Inc.). Since Feb 16, 2024, Faraz Ali has reported 0 open-market buys worth $0 and 8 open-market sells worth $94k, the latest filed on Aug 17, 2026.
A track record needs three past buys with six months of prices behind them; Faraz Ali has 0, so none is measured yet.
The newest scored trade: sold $16k of TNYA on Aug 17, 2026, filed Aug 17, 2026, scored 33 (weak). In the last 12 months: 0 buys worth $0 and 4 sells worth $32k.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
TNYA: Tenaya Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 33Weak | Tenaya Therapeutics, Inc. | $16k 22,232 shares | -5% | +27% from low-67% from high | |
| 40Moderate | Tenaya Therapeutics, Inc. | $2,690 3,390 shares | -1% | +82% from low-63% from high | |
| 40Moderate | Tenaya Therapeutics, Inc. | $9,557 14,862 shares | -3% | +63% from low-70% from high | |
| 40Moderate | Tenaya Therapeutics, Inc. | $4,158 3,126 shares | -1% | +225% from low-67% from high | |
| 40Moderate | Tenaya Therapeutics, Inc. | $18k 14,533 shares | -5% | +225% from low-67% from high | |
| 40Moderate | Tenaya Therapeutics, Inc. | $1,412 3,189 shares | -1% | +16% from low-88% from high | |
| 33Weak | Tenaya Therapeutics, Inc. | $5,245 9,741 shares | -3% | - | |
| 31Weak | TNYAsell Tenaya Therapeutics, Inc. | $37k 6,358 shares | -5% | +265% from low-17% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Aug 17, 2026 | TNYA Tenaya Therapeutics, Inc. | 22,232 0.01% of outstanding | $16k | Aug 17, 2026 | none |
| Feb 17, 2026 | TNYA Tenaya Therapeutics, Inc. | 14,862 0.01% of outstanding | $9,557 | Feb 17, 2026 | none |
| Aug 18, 2025 | TNYA Tenaya Therapeutics, Inc. | 14,533 0.01% of outstanding | $18k | Aug 18, 2025 | none |
| Mar 10, 2025 | TNYA Tenaya Therapeutics, Inc. | 9,741 0.01% of outstanding | $5,245 | Mar 10, 2025 | none |
| Feb 16, 2024 | TNYA Tenaya Therapeutics, Inc. | 6,358 0.01% of outstanding | $40k | Feb 16, 2024 | none |
Transactions
Every row this insider has filed, 31 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 10, 2026 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Common Stock | +122,000 | $0.00 | $0 | 539,782 | 32 d ago |
| Sep 10, 2026 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +732,500 | $0.00 | $0 | 732,500 | 32 d ago |
| Aug 17, 2026 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -5,837 | $0.71 | $4,143 | 434,177 | Aug 17, 2026 |
| Aug 17, 2026 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -3,969 | $0.71 | $2,817 | 430,208 | Aug 17, 2026 |
| Aug 17, 2026 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -5,020 | $0.71 | $3,563 | 425,188 | Aug 17, 2026 |
| Aug 17, 2026 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -7,406 | $0.71 | $5,256 | 417,782 | Aug 17, 2026 |
| May 18, 2026 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -3,390 | $0.79 | $2,690 | 440,014 | May 19, 2026 |
| Feb 17, 2026 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -5,851 | $0.64 | $3,762 | 452,415 | Feb 17, 2026 |
| Feb 17, 2026 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -3,979 | $0.64 | $2,559 | 448,436 | Feb 17, 2026 |
| Feb 17, 2026 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -5,032 | $0.64 | $3,236 | 443,404 | Feb 17, 2026 |
| Feb 3, 2026 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Common Stock | +158,600 | $0.00 | $0 | 458,266 | Feb 5, 2026 |
| Feb 3, 2026 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +952,250 | $0.00 | $0 | 952,250 | Feb 5, 2026 |
| Nov 17, 2025 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -3,126 | $1.33 | $4,158 | 299,666 | Nov 17, 2025 |
| Aug 18, 2025 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -5,720 | $1.25 | $7,167 | 311,605 | Aug 18, 2025 |
| Aug 18, 2025 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -3,893 | $1.25 | $4,878 | 307,712 | Aug 18, 2025 |
| Aug 18, 2025 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -4,920 | $1.25 | $6,165 | 302,792 | Aug 18, 2025 |
| May 16, 2025 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -3,189 | $0.44 | $1,412 | 317,325 | May 16, 2025 |
| Mar 10, 2025 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -5,794 | $0.54 | $3,119 | 324,461 | Mar 10, 2025 |
| Mar 10, 2025 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -3,947 | $0.54 | $2,125 | 320,514 | Mar 10, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Common Stock | +107,500 | $0.00 | $0 | 295,831 | Feb 7, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Common Stock | +34,424 | $0.00 | $0 | 330,255 | Feb 7, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +650,000 | $0.00 | $0 | 650,000 | Feb 7, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -353,271 | - | - | 0 | Feb 7, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +353,271 | - | - | 353,271 | Feb 7, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -161,214 | - | - | 0 | Feb 7, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +161,214 | - | - | 161,214 | Feb 7, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -401,390 | - | - | 0 | Feb 7, 2025 |
| Feb 6, 2025 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +401,390 | - | - | 401,390 | Feb 7, 2025 |
| Feb 23, 2024 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Common Stock | +85,000 | $0.00 | $0 | 198,079 | Feb 27, 2024 |
| Feb 23, 2024 | TNYA Tenaya Therapeutics, Inc. | AGrant or award Stock Option (Right to buy)derivative | +505,000 | $0.00 | $0 | 505,000 | Feb 27, 2024 |
| Feb 16, 2024 | TNYA Tenaya Therapeutics, Inc. | SOpen-market sale Common Stock | -6,358 | $5.86 | $37k | 113,079 | Feb 16, 2024 |
Questions about Faraz Ali
Answered from the filings on this page, as of the latest one.
Is Faraz Ali buying or selling?
In the last 12 months Faraz Ali reported 0 open-market buys worth $0 and 4 open-market sells worth $32k on SEC Form 4; the latest was sold $16k of TNYA on Aug 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Faraz Ali's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Faraz Ali has 0.
Where does Faraz Ali file Form 4?
Faraz Ali has filed Form 4 at TNYA (Tenaya Therapeutics, Inc.) as Chief Executive Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.